Sugi Predict

Sugi Predict / Targets / KIT

KIT

Mast/stem cell growth factor receptor Kit · P10721 · KIT on Sugi Atlas →

268,811 patent compounds predicted against KIT, 181,169 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL42089 SCHEMBL42089 0.60 16/20
Linifanib Linifanib (SCHEMBL93804) 1.00 14/20
SCHEMBL63357 SCHEMBL63357 0.55 14/20
SCHEMBL90952 SCHEMBL90952 0.51 14/20
Imatinib Imatinib (SCHEMBL3827) 1.00 12/20
Imatinib Imatinib (SCHEMBL8217) 1.00 12/20
SCHEMBL71900 SCHEMBL71900 0.51 12/20
Nilotinib Nilotinib (SCHEMBL7901) 1.00 11/20
SCHEMBL95010 SCHEMBL95010 0.81 11/20
SCHEMBL90883 SCHEMBL90883 0.52 9/20
SCHEMBL60289 SCHEMBL60289 0.48 9/20
SCHEMBL58735 SCHEMBL58735 0.47 9/20
Vatalanib Vatalanib (SCHEMBL18286) 1.00 8/20
SCHEMBL9485 SCHEMBL9485 0.81 8/20
Pazelliptine Pazelliptine (SCHEMBL62441) 0.73 8/20
SCHEMBL65790 SCHEMBL65790 0.60 8/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL58421) 0.59 8/20
SCHEMBL58313 SCHEMBL58313 0.59 8/20
SCHEMBL58543 SCHEMBL58543 0.57 8/20
SCHEMBL60464 SCHEMBL60464 0.57 8/20

Clinical trials — most relevant to KIT by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Imatinib in KIT-negative Systemic Mastocytosis PHASE4COMPLETED
Interest of Denosumab Treatment in Osteoporosis Associated to Systemic Mastocytosis PHASE3COMPLETED
Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis Unresponsive to Optimal Symptomatic Treatment PHASE3UNKNOWN
Masitinib in the Treatment of Patients With Severe Uncontrolled Asthma and Elevated Eosinophil Levels PHASE3COMPLETED
Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis PHASE3COMPLETED
Effects of cKit Inhibition by Imatinib in Patients With Severe Refractory Asthma (KIA) PHASE2COMPLETED
Evaluation of Cabozantinib in Metastatic Renal Cell Carcinoma (mRCC) With Brain Metastases PHASE2COMPLETED
Combination of Midostaurin and Gemtuzumab Ozogamicin in First-line Standard Therapy for Acute Myeloid Leukemia (MOSAIC) PHASE1/PHASE2RECRUITING
Phase 2 Midostaurin in Aggressive Systemic Mastocytosis and Mast Cell Leukemia PHASE2COMPLETED
Sunitinib as a Second-line Treatment for Patients With Recurrent Small Cell Lung Cancer PHASE2COMPLETED
Efficiency of Imatinib Treatment After 10 Years of Treatment in Patients With Gastrointestinal Stromal Tumours (GIST) (Gist-Ten) PHASE2RECRUITING
Imatinib Mesylate in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Primary Peritoneal Cancer PHASE2COMPLETED
Imatinib in Patients With Mucosal or Acral/Lentiginous Melanoma PHASE2COMPLETED
A Randomized, Double-Blind, Placebo-Controlled Study of Omalizumab for Idiopathic Anaphylaxis PHASE2COMPLETED
Phase II Study of the Optimal Scheme of Administration of Pazopanib in Thyroid Carcinoma PHASE2COMPLETED
Stem Cell Transplantation to Treat Systemic Mastocytosis PHASE2COMPLETED
Trial to Assess the Efficacy of Midostaurin (PKC412) in Patients With c-KIT or FLT3-ITD Mutated t(8;21) AML PHASE2COMPLETED
Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase Enzymes PHASE2COMPLETED
Masitinib in Patients With Mastocytosis With Handicap and Bearing the D816V Mutation PHASE2COMPLETED
Midostaurin in Indolent Systemic Mastocytosis PHASE2UNKNOWN
Imatinib Mesylate in Treating Patients With Relapsed or Refractory Solid Tumors of Childhood PHASE2COMPLETED
Regorafenib, C-kit Mutated Malignant Melanoma, 2nd Line Therapy PHASE2UNKNOWN
Preoperative Imatinib and Fampridine in KIT Mutant Gastrointestinal Stromal Tumor PHASE1RECRUITING
Screening Study for KIT D816V Mutated Mast Cell Disease in Select Populations nanRECRUITING
Molecular Mechanisms and Diagnosis of Mastocytosis nanCOMPLETED
Peripheral Blood KIT-D816V Mutation in Adult Systemic Mastocytosis nanRECRUITING
Cutaneous Mastocytosis in Children: Analysis of Somatic and Germline Mutations nanCOMPLETED
Study of Factors Regulating Mast Cell Proliferation nanRECRUITING
Blood Factors in Mastocytosis and Unexplained Anaphylaxis and Flushing nanCOMPLETED
An Observational Study in Participants With Indolent Systemic Mastocytosis (ISM) nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a KIT binder may also engage these)

ProteinNameSimilarity
Q76II0 — 1.000 Q76II0 →
Q28317 — 1.000 Q28317 →
Q2HWD6 — 1.000 Q2HWD6 →
Q28889 — 1.000 Q28889 →
P05532 — 1.000 P05532 →
Q91909 — 1.000 Q91909 →
Q8AXC7 — 1.000 Q8AXC7 →
P43481 — 1.000 P43481 →
Q9DE49 — 1.000 Q9DE49 →
P79750 — 1.000 P79750 →
Q00495 — 1.000 Q00495 →
P26619 — 1.000 P26619 →
Q08156 — 1.000 Q08156 →
P20786 — 1.000 P20786 →
Q86PM4 — 0.999 Q86PM4 →
Q09147 — 0.999 Q09147 →
O08775 — 0.998 O08775 →
P35918 — 0.998 P35918 →
Q8JFR5 — 0.998 Q8JFR5 →
KDR Vascular endothelial growth factor receptor 2 0.998 landscape →
Q9I8N6 — 0.998 Q9I8N6 →
O97799 — 0.998 O97799 →
Q8AXB3 — 0.997 Q8AXB3 →
Q4H3K6 — 0.996 Q4H3K6 →
P79701 — 0.996 P79701 →
O18016 — 0.996 O18016 →
MUSK Muscle, skeletal receptor tyrosine-protein kinase 0.996 landscape →
P79749 — 0.995 P79749 →
P04157 — 0.995 P04157 →
PDGFRA Platelet-derived growth factor receptor alpha 0.995 landscape →